Comparison of HIV prevalence, incidence, and viral load suppression in Zambia population-based HIV impact assessments from 2016 and 2021.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
15 Jan 2024
Historique:
medline: 16 1 2024
pubmed: 16 1 2024
entrez: 16 1 2024
Statut: aheadofprint

Résumé

The Zambian government has implemented a public health response to control the HIV epidemic in the country. Zambia conducted a population-based HIV impact assessment (ZAMPHIA) survey in 2021 to assess the status of the HIV epidemic to guide its public health programs. ZAMPHIA 2021 was a cross-sectional two-stage cluster sample household survey among persons aged ≥15 years conducted in Zambia across all 10 provinces. Consenting participants were administered a standardized questionnaire and whole blood was tested for HIV according to national guidelines. HIV-1 viral load (VL), recent HIV infection, and antiretroviral medications were tested for in HIV-seropositive samples. Viral load suppression (VLS) was defined as <1000 copies/ml. ZAMPHIA 2021 results were compared to ZAMPHIA 2016 for persons aged 15-59 years (i.e., the overlapping age ranges). All estimates were weighted to account for nonresponse and survey design. During ZAMPHIA 2021, of 25 483 eligible persons aged ≥15 years, 18 804 (73.8%) were interviewed and tested for HIV. HIV prevalence was 11.0% and VLS prevalence was 86.2% overall, but was <80% among people living with HIV aged 15-24 years and in certain provinces. Among persons aged 15-59 years, from 2016 to 2021, HIV incidence declined from 0.6% to 0.3% (P-value: 0.07) and VLS prevalence increased from 59.2% to 85.7% (P-value: <0.01). Zambia has made substantial progress toward controlling the HIV epidemic from 2016 to 2021. Continued implementation of a test-and-treat strategy, with attention to groups with lower VLS in the ZAMPHIA 2021, could support reductions in HIV incidence and improve overall VLS in Zambia.

Sections du résumé

BACKGROUND BACKGROUND
The Zambian government has implemented a public health response to control the HIV epidemic in the country. Zambia conducted a population-based HIV impact assessment (ZAMPHIA) survey in 2021 to assess the status of the HIV epidemic to guide its public health programs.
METHODS METHODS
ZAMPHIA 2021 was a cross-sectional two-stage cluster sample household survey among persons aged ≥15 years conducted in Zambia across all 10 provinces. Consenting participants were administered a standardized questionnaire and whole blood was tested for HIV according to national guidelines. HIV-1 viral load (VL), recent HIV infection, and antiretroviral medications were tested for in HIV-seropositive samples. Viral load suppression (VLS) was defined as <1000 copies/ml. ZAMPHIA 2021 results were compared to ZAMPHIA 2016 for persons aged 15-59 years (i.e., the overlapping age ranges). All estimates were weighted to account for nonresponse and survey design.
RESULTS RESULTS
During ZAMPHIA 2021, of 25 483 eligible persons aged ≥15 years, 18 804 (73.8%) were interviewed and tested for HIV. HIV prevalence was 11.0% and VLS prevalence was 86.2% overall, but was <80% among people living with HIV aged 15-24 years and in certain provinces. Among persons aged 15-59 years, from 2016 to 2021, HIV incidence declined from 0.6% to 0.3% (P-value: 0.07) and VLS prevalence increased from 59.2% to 85.7% (P-value: <0.01).
DISCUSSION CONCLUSIONS
Zambia has made substantial progress toward controlling the HIV epidemic from 2016 to 2021. Continued implementation of a test-and-treat strategy, with attention to groups with lower VLS in the ZAMPHIA 2021, could support reductions in HIV incidence and improve overall VLS in Zambia.

Identifiants

pubmed: 38227572
doi: 10.1097/QAD.0000000000003834
pii: 00002030-990000000-00435
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Auteurs

Lloyd B Mulenga (LB)

Ministry of Health.
University Teaching Hospital.
University of Zambia, School of Medicine.

Jonas Z Hines (JZ)

U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Kristen A Stafford (KA)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Kumbutso Dzekedzeke (K)

Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation-an affiliate of the University of Maryland, Baltimore, Lusaka, Zambia.

Suilanji Sivile (S)

Ministry of Health.
University Teaching Hospital.

Brianna Lindsay (B)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Faith Ussery (F)

U.S. Centers for Disease Control and Prevention, Atlanta, USA.

Alash'le Abimiku (A)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Peter Minchella (P)

U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Thomas Stevens (T)

U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Brave Hanunka (B)

U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Tina Chisenga (T)

Ministry of Health.

Aaron Shibemba (A)

University Teaching Hospital.

Sombo Fwoloshi (S)

Ministry of Health.
University Teaching Hospital.

Mwiche Siame (M)

Ministry of Health.

John Mutukwa (J)

Ministry of Health.

Lameck Chirwa (L)

University Teaching Hospital.

Mpanji Siwingwa (M)

University Teaching Hospital.
University of Zambia, School of Medicine.

Gina Mulundu (G)

University Teaching Hospital.
University of Zambia, School of Medicine.

Chinedu Agbakwuru (C)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Mervi Detorio (M)

U.S. Centers for Disease Control and Prevention, Atlanta, USA.

Simon G Agolory (SG)

U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Mwaka Monze (M)

Ministry of Health.
University Teaching Hospital.

Megan Bronson (M)

U.S. Centers for Disease Control and Prevention, Atlanta, USA.

Classifications MeSH